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Abstract
Consensus guidelines recommend dopamine agonists (DAs) as the mainstay treatment for prolactinomas. In most patients, 
DAs achieve tumor shrinkage and normoprolactinemia at well tolerated doses. However, primary or, less often, secondary 
resistance to DAs may be also encountered representing challenging clinical scenarios. This is particularly true for aggres-
sive prolactinomas in which surgery and radiotherapy may not achieve tumor control. In these cases, alternative medical 
treatments have been considered but data on their efficacy should be interpreted within the constraints of publication bias 
and of lack of relevant clinical trials. The limited reports on somatostatin analogues have shown conflicting results, but cases 
with optimal outcomes have been documented. Data on estrogen modulators and metformin are scarce and their usefulness 
remains to be evaluated. In many aggressive lactotroph tumors, temozolomide has demonstrated optimal outcomes, whereas 
for other cytotoxic agents, tyrosine kinase inhibitors and for inhibitors of mammalian target of rapamycin (mTOR), higher 
quality evidence is needed. Finally, promising preliminary results from in vitro and animal reports need to be further assessed 
and, if appropriate, translated in human studies.
Keywords Prolactinoma · Dopamine agonist · Resistance · Aggressive prolactinoma
Introduction
Prolactinomas are the most common pituitary neuroendo-
crine tumors (PitNETs) with a prevalence ranging from 6–10 
to 60 per 100,000 patients [1–3]. Most of them arise from 
monoclonal expansion of lactotroph cells. Less than 5% 
of the cases are related to a hereditary syndrome, such as 
Multiple Endocrine Neoplasia 1 and 4 (MEN1 and MEN4, 
respectively), familial isolated pituitary adenoma (FIPA) or 
Carney complex [4–6].
The clinical manifestations of prolactinomas relate to 
mass-effects (most frequently visual field defects, head-
aches and hypopituitarism) and/or to hyperprolactinemia-
related consequences (hypogonadism and its sequelae and 
galactorrhea). Primary goals of treatment are reduction in 
tumor size, achievement of normal prolactin and restoration 
of gonadal function [7, 8]. The treatment of prolactinomas 
is unique amongst the PitNETs, since they are the only type 
of pituitary tumor in which first-line approach is medical 
therapy [with dopamine agonists (DA)] rather than surgery. 
Consensus guidelines recommend cabergoline in preference 
to other DAs, such as bromocriptine and quinagolide [7]. 
This is based on studies showing more optimal tolerability 
profile and higher efficacy in achieving normoprolactine-
mia and tumor shrinkage with this agent [9–12], attributed 
to higher affinity to D2 receptor and more potent cytocidal 
effect in tumor cells (compared with bromocriptine) [13]. 
In addition, a meta-analysis has underlined that DAs, in this 
case bromocriptine, can successfully manage various clinical 
 * N. Karavitaki 
 n.karavitaki@bham.ac.uk
1 Department of Endocrinology, Diabetes and Metabolism, 
Centro Hospitalar Universitário de São João, Porto, Portugal
2 Faculty of Medicine of University of Porto, Porto, Portugal
3 Instituto de Investigação e Inovação em Saúde, University 
of Porto, Porto, Portugal
4 Institute of Metabolism and Systems Research (IMSR), 
College of Medical and Dental Sciences, University 
of Birmingham, IBR Tower, Level 2, Birmingham B15 2TT, 
UK
5 Centre for Endocrinology, Diabetes and Metabolism, 
Birmingham Health Partners, Birmingham, UK
6 Department of Endocrinology, Queen Elizabeth Hospital, 
University Hospitals Birmingham NHS Foundation Trust, 
Birmingham, UK
 Pituitary
1 3
manifestations seen in patients with prolactinoma, including 
86% of those with galactorrhea, 78% with amenorrhea, 67% 
with sexual dysfunction, 67% with visual field defects and 
53% of patients with infertility [14].
A small subset of patients does not respond to DAs (pri-
mary resistance). It should be noted, however, that defini-
tions of resistance are highly variable throughout the litera-
ture, rendering the comparison of response rates and relevant 
predictors rather challenging. Practice guidelines for hyper-
prolactinemia suggest that a failure to achieve normal pro-
lactin on maximally tolerated doses of DAs and a failure to 
achieve 50% reduction in tumor size should be regarded as 
DA-resistance [7]. This definition has also been acknowl-
edged by the other publications [15, 16]. The maximally tol-
erated doses vary amongst patients and can be up to 12 mg 
weekly for cabergoline and 30 mg daily for bromocriptine 
[15–17]. In common clinical practice, the mean maximum 
dose of cabergoline (the most frequently used DA) is around 
4 mg per week [18]. There is no agreement on the minimum 
duration of treatment and it would seem reasonable to sug-
gest at least 6 months on the highest tolerated DA dose [17]. 
It is also worth mentioning that the relative importance of 
tumor shrinkage as a criterion for resistance needs to be 
challenged in adenomas in which, although reduction in 
size has not been achieved, they are not causing pressure 
effects. Consensus recommendations recognize that failure 
to restore fertility may also reflect treatment resistance, and 
that some patients might have a discordant biochemical and 
tumoral response, further complicating the establishment of 
a standard definition [7]. It should be further underlined that 
previous studies have used different cut-offs, such as 50% 
decrease in prolactin levels or 30% reduction in craniocaudal 
diameter of the tumor [19, 20]. Irrespective of the criteria 
adopted for defining DA resistance, decisions on continuing 
treatment with these agents should also rely on the clinical 
benefit (e.g. restoration of gonadal function, resolution of 
mass effects and particularly visual disturbances, absence of 
tumor growth) achieved for each individual patient.
Primary DA-resistance has been reported in approxi-
mately 20–30% of the patients on bromocriptine, and in 
around 10% of those on cabergoline [15, 17, 21]. Yet, 
when focusing on macroprolactinomas only, cabergoline 
fails to lead to normoprolactinemia in 17% of the cases and 
to tumor shrinkage in 29% of them [15]. Further studies 
have suggested that tumor size and invasiveness (namely 
cavernous sinus extension), younger age at diagnosis and 
male gender are predictors of lower response [18, 22–24]. 
Decreased expression of D2 dopamine receptors in tumor 
cells, alterations in other receptors modulating dopamine 
receptors [e.g. nerve growth factor receptor (NGFR)], 
changes in downstream cascades (e.g. in G protein subu-
nit), increased angiogenic markers, and increased fibro-
sis through disruptions in the transforming growth factor 
(TGF)-β1 pathway have all been suggested as possible 
mechanisms playing a role in DA-resistance [25–29]. 
However, an extensive audit of these mechanisms is out-
side the scope of this review.
Secondary (or acquired) resistance to DAs is very rare 
and describes patients that initially responded to DA but 
later showed increasing prolactin levels and/or tumor 
enlargement. It should be pointed out that some patients 
who initially responded to bromocriptine but then acquired 
some degree of resistance have benefited from a switch to 
cabergoline, and, therefore, they should not be regarded 
as truly DA-resistant [30]. To the best of our knowledge, 
only six cases in the literature have reported true second-
ary DA-resistance, in some of them 10 years after an initial 
response [31–35]. The histologic characteristics of these 
tumors were heterogenous, ranging from adenomas with-
out worrisome features to atypical adenomas with a high 
cell proliferation index. It is unknown if the mechanisms 
underlying secondary DA-resistance differ from those 
associated with primary resistance.
Current practice guidelines recommend several possible 
approaches for patients with DA-resistant prolactinomas 
[7]. In cases resistant to bromocriptine, a switch to caber-
goline is recommended, based on the superior results of 
this agent when compared to other DAs, as previously dis-
cussed, and on studies reporting prolactin normalization in 
80–85% of the patients after this change [11, 36]. Switch 
to quinagolide can not be excluded, although a meta-anal-
ysis found no differences when bromocriptine and quina-
golide were compared for various clinical and biochemical 
outcomes [37]. Surgical removal is a further approach with 
remission rates of 63–72% and 32–60% for micro- and for 
non-invasive macroprolactinomas, respectively; these rates 
also include patients offered surgery due to DA intolerance 
[38, 39]. Radiotherapy is an alternative option with studies 
reporting normoprolactinemia rates of 15–50% that can be 
further increased when DA therapy is added (40–100%) 
[40]. Malignant and aggressive prolactinomas represent a 
rare and difficult setting of DA-resistance posing signifi-
cant therapeutic challenges [41, 42].
The above described options to overcome DA-resistance 
may not always be successful and in this setting, the value 
of alternative medical agents has been investigated. In the 
following sections, we have reviewed the available litera-
ture on different pharmacological options in DA-resistant 
prolactinomas.
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Alternative medical treatments
Somatostatin analogues
Somatostatin analogues (SSAs) have a well-defined role in 
the management algorithms of corticotropinomas, soma-
totropinomas and thyreotropinomas [43–45].
Immunochemistry mapping of somatostatin receptors 
(SSTR) has revealed that all SSTR types are present in 
prolactinomas;  SSTR5 were particularly frequent, fol-
lowed by  SSTR2A and  SSTR1 [46–48]. However, clinical 
studies on the use of SSAs in prolactinomas have shown 
conflicting results. In the largest published case series, 
Sosa-Eroza et al. presented five patients with DA-resist-
ant prolactinoma treated with octreotide LAR (20 mg 
for 6–13 months) in addition to cabergoline. Normopro-
lactinemia was not achieved in any of the patients but two 
of them had > 80% drop in prolactin and a > 90% reduction 
in tumor volume. The remaining three had no significant 
benefit [49]. A summary of the reported cases from the 
literature highlighting the mixed outcomes is shown in 
Table 1 [50–53].
A theoretical advantage of the second-generation SSA 
pasireotide over the first-generation ones (octreotide and lan-
reotide) could be postulated, considering its greater affinity 
for  SSTR5. Nevertheless, in vitro analyses have provided 
conflicting results [47, 54, 55]. The first report of a patient 
with prolactinoma treated with pasireotide was recently 
published, presenting a case not controlled after treatment 
with the three available DAs and undergoing two surgi-
cal procedures (Table 1) [56]. Pasireotide was then tried, 
achieving prolactin normalization in one month and tumor 
stabilization that persisted during the 7-year follow-up. No 
side effects were reported apart from slight deterioration of 
glycemic control (HbA1c increased from 5.7 to 6.2%). After 
this report, a second one described a DA-resistant macropro-
lactinoma also successfully treated with this agent [57]; con-
sidering that the tumor had a higher immunoreactivity score 
for  SSTR5 than for  SSTR2, and after attempting lanreotide 
Autogel without biochemical/imaging success, pasireotide 
was used leading to normoprolactinemia and tumor shrink-
age. Once again, minor hyperglycemia was the only side 
effect reported (HbA1c increased from 5.4 to 6.3%).
It has been previously demonstrated that the  SSTR1 
subtype is overexpressed in DA-resistant tumors suggest-
ing that this could be a promising therapeutic target [47]. 
Despite this finding, an in vitro study showed that a  SSTR1 
ligand was not highly effective in suppressing prolactin 
levels and the role of this receptor in prolactin secretion is 
still not completely understood [47].
All the aforementioned studies include a small num-
ber of patients not allowing identification of predictors of 
response to SSA treatment. However, it seems likely that 
the SSTR expression profile in lactotroph adenomas is not 
the only parameter associated with the high variability in 
the outcomes. Other less well-understood aspects of SSTR 
biology, such as receptor homo- and hetero- dimerization 
and additional downstream pathways may also play a role 
[58]. Further methodologically sound studies are required 
to clarify the place of SSAs in the treatment algorithm 
of DA-resistant prolactinomas. Until then, a therapeutic 
trial in selected patients with aggressive and DA-resistant 
prolactinomas could be considered as a possible option.
Estrogen modulators
Estrogens stimulate prolactin secretion and lactotroph cell 
proliferation [59, 60]. Lactotroph hyperplasia leading to 
gland enlargement during pregnancy and breast-feeding 
support these findings and suggests that estrogens may be 
potential therapeutic targets in prolactinomas [61]. On the 
other hand, it is of note that prolactinomas in men are char-
acterized by lower estrogen receptor alpha (ERα) expression 
which is related to higher tumor grades, resistance to treat-
ment, and an overall worse prognosis [62].
A number of studies have evaluated the potential role of 
selective estrogen receptor modulators (SERMs) in prolac-
tinoma patients (Table 2). Tamoxifen was used in 10 women 
previously considered bromocriptine-resistant, inducing 
a moderate reduction of prolactin in 6 of them [63]. Two 
smaller studies conducted in the pre-cabergoline era and 
including patients not clearly fulfilling the DA resistance cri-
teria showed inconsistent results on the efficacy of this drug 
[64, 65]. Raloxifene, another SERM, resulted in minimal 
decrease in prolactin levels (mean reduction of 8.3 ng/mL) 
in 10 out of 14 patients, with the remaining ones considered 
as non-responders [66]. The drug was then stopped in 8 of 
them, as the absolute change in prolactin values was felt to 
be too small to justify this treatment. Fluvestrant, a selec-
tive estrogen receptor degrader (SERD) without the agonist 
properties of SERMs, inhibited prolactin secretion in rat 
prolactinoma models, but its usefulness in patients remains 
to be determined in clinical studies [37, 67–69].
Aromatase inhibition blocks the conversion of testoster-
one to estradiol and it could possibly mitigate the estrogen-
induced lactotroph proliferation [70]. A higher expression 
of this enzyme in prolactinomas and its correlation with 
tumor invasiveness has been previously shown, but this has 
not been confirmed in DA-resistant prolactinomas in males 
[71, 72]. Fadrozole administration in rats inhibited the pro-
liferation of prolactin-positive cells and led to reduced pro-
lactin levels [73]. Two publications have reported optimal 
outcomes with the use of aromatase inhibitors in DA-resist-
ant patients with persistent hypogonadism [74, 75]. In the 
first case, prolactin increased after testosterone was added 
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to cabergoline therapy. Anastrozole (1 mg daily) was then 
started and prolactin levels dropped by 80% in 3 months. 
Tumor size change was not reported [74]. In the second 
patient, a 36-year-old male, the introduction of testoster-
one replacement and human chorionic gonadotropin (hCG) 
therapy (in order to achieve fertility) led to raised prolac-
tin levels. Letrozole (2.5 mg daily) was tried leading to a 
74% decrease in prolactin after 32 months, improved sperm 
count and fertility [75]. In both cases, authors hypothesized 
that testosterone aromatization to estradiol and subsequent 
Table 1  Somatostatin analogues treatment in DA-resistant prolactinomas
A plus sign (+) in the PRL and volume changes indicate an increase in prolactin levels or tumor size, respectively, while a minus sign (−) imply 
a decrease in these variables
SSA somatostatin analogue, PRL prolactin, DA dopamine agonist, CBG cabergoline, TMZ temozolomide, RT radiotherapy, LAR long-acting 
release, NS not stated, BRC bromocriptine, CTX chemotherapy, QNG quinagolide
Study No. of 
patients
Tumor Previous treat-
ments
SSA regime Duration of treat-
ment
Normal PRL (% 
change in PRL 
from baseline)
Tumor shrink-
age (% volume 
change)
Soza-Eroza et al. 
[47]
5 DA-resistant 
macroprolacti-
nomas
CBG (max 
4.5 mg/week), 
surgery, TMZ, 
RT, tamoxifen
Octreotide LAR 
(20 mg/month)
12 months No (+ 3%) Minor (− 9%)
CBG (max 3 mg/
week)
13 months No (+ 1%) Minor (− 5%)
CBG (max 3 mg/
week), surgery
10 months No (− 97%) Yes (− 93%)
CBG (max 
4.5 mg/week), 
surgery
10 months No (− 82%) Yes (− 94%)
CBG (max 
7.5 mg/week), 
surgery
3 months No (+ 5%) Minor (− 10%)
Fusco et al. [48] 1 DA-resistant 
macroprolacti-
noma
CBG (max 3 mg/
week), surgery
Octreotide LAR 
(20 mg/month)
NS Yes No
Walker et al. [49] 2 DA-resistant 
lactotroph carci-
nomas
BRC (max 30 mg/
day), surgery, 
RT, CTX
Octreotide 
(100 μg 
8-hourly)
NS No No
BRC (max 20 mg/
day), surgery, 
RT
NS NS NS NS
Baldari et al. [50] 1 DA-resistant 
macroprolacti-
noma
BRC (max dose 
NS), CBG 
(0.5 mg/week), 
surgery, RT
Octreotide LAR 
(30 mg single 
dose)
Single dose No No
Giuffrida et al. 
[51]
1 DA-resistant 
macroprolacti-
noma
CBG (max dose 
NS), surgery, 
RT
Octreotide LAR 
(30 mg single 
dose)
Single dose No No
Coopmans et al. 
[55]
1 DA-resistant 
macroprolacti-
noma
BRC (max 
7.5 mg/day), 
CBG (max 
7 mg/week), 
surgery, RT
Lanreotide Auto-
gel (120 mg/
month)
10 months No (+ 36%) No
Pasireotide LAR 
(60 mg/month 
after lanreotide 
was discontin-
ued)
31 months Yes (− 100%) Yes (-72%)
Lasolle et al. [54] 1 DA-resistant 
macroprolacti-
noma
BRC (max 25 mg/
day), QNG 
(max 225 μg/
day), CBG 
(4.5 mg/week), 
surgery
Pasireotide LAR 
(initially 60 mg 
every 28 days, 
then 20 mg 
every 5 weeks)
7 years Yes No
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estrogen-stimulated prolactin release were the main drives 
for the prolactin levels increase and that aromatase inhibitors 
blocked this effect.
Overall, data on the use of estrogen modulators in prolac-
tinomas not responding to DAs are limited and inconclusive.
Metformin
Recently, metformin has attracted attention as a drug able 
to reduce lactotroph cells proliferation and to promote their 
apoptosis, both in rat xenografts and in human prolactinoma 
cell cultures [76, 77]. Metformin-dependent activation of 
AMP‐activated protein kinase (AMPK) has been proposed 
as the underlying mechanism in accordance with the action 
of metformin in other types of tumors [78]. The cascade 
of events downstream the AMPK activation leading to the 
above effects are not fully understood, but estrogen receptor 
downregulation seems to be involved [77].
To date, only one study has described two bromocriptine-
resistant prolactinoma patients (on maximum dose of 15 mg/
day) treated with metformin [79]. In the first case, a patient 
with prolactin levels fluctuating between 70 and 488 ng/
mL was started metformin (1500 mg/day) after the diag-
nosis of diabetes mellitus and her prolactin was decreased 
to 56 ng/mL in 3 months and to 28 ng/mL in 5 months. 
Tumor shrinkage was also reported on both MRIs performed 
5 and 10 months after drug initiation. Based on these find-
ings, metformin was tried in a second patient of the same 
center. He presented with a giant prolactinoma that exhib-
ited a good biochemical response to bromocriptine (prolac-
tin levels decreased from 1293 to 17.7 ng/mL) but without 
tumor shrinkage. After starting metformin, prolactin levels 
decreased to 2.08 mg/dL in 3 months and a 40% reduction 
in tumor volume (also associated with hemorrhage) was 
observed.
Temozolomide
Temozolomide (TMZ) is considered the first-line chemo-
therapeutic agent for aggressive pituitary tumors and carci-
nomas [80–82]. TMZ treatment has been reported in more 
than 30 lactotroph invasive adenomas/carcinomas, with 
approximately 50% of the patients exhibiting a decrease of 
more than 30% in tumor volume [83, 84].Several reports 
have shown dramatic improvements including disappear-
ance of metastases, substantial primary tumor reduction and 
normalization of prolactin [80, 85–88]. Various regimens 
have been used and the administration of 50–200 mg/m2 for 
five days in 28 days cycles is the most frequently described 
protocol [83]. However, a second course of TMZ, even in 
patients previously considered as responders, has shown 
less favorable outcomes [89–91]. Amongst those cases, two 
lactotroph aggressive tumors/carcinomas were identified in 
which TMZ initial therapy led to good results, ranging from 
a remarkable 98% reduction in prolactin levels to a 25% 
regression in tumor size. However, when these tumors pro-
gressed and a second course of TMZ was offered, the results 
were disappointing, suggesting an acquired TMZ-resistance 
mechanism that remains to be fully clarified [89, 90].
Several studies have looked at possible predictors of 
TMZ response in pituitary tumors. A lower expression of 
O6-methylguanine-DNA methyltransferase (MGMT), a 
Table 2  Selective estrogen receptor modulators (SERM) treatment in prolactinomas
A plus sign (+) in the PRL and volume changes indicate an increase in the prolactin levels or tumor size, respectively, while a minus sign (−) 
imply a decrease in these variables
PRL prolactin, DA dopamine agonist, BRC bromocriptine, NS not stated, CBG cabergoline
Study No. of patients Tumor Previous treat-
ments
Drug regime Duration of 
treatment
% Change 
in PRL from 
baseline
Tumor shrink-
age (% volume 
change)
Volker et al. [60] 10 DA-resistant 
prolactinomas
BRC (median 
dose 5 mg/
day), Surgery 
(n = 2)
Tamoxifen 
(10–20 mg/
day)
4 weeks Mean − 35% 
(Normal PRL 
in 60%)
NS
Lamberts et al. 
[61]
2 Prolactinomas 
(not DA-
resistant)
NS BRC vs. BRC/
Tamofixen 
(20 mg/day)
36 h 45% vs. − 44% NS
Lamberts et al. 
[62]
8 Invasive prolac-
tinomas (not 
DA-resistant)
surgery (n = 6) Tamoxifen 
(20 mg/day)
5 days Mean − 20% NS
Choudhary et al. 
[63]
14 Prolactinomas 
(not DA-
resistant)
CGB (median 
dose 3 mg/
week) (n = 13), 
BRC (15 mg/
day) (n = 1)
Raloxifene 
(60 mg/day)
Mean 3 months Mean − 15% NS
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DNA-repair protein that counteracts the effects of TMZ, is 
significantly correlated with the effectiveness of the drug 
[89, 92, 93]. This observation led to the recommendation 
of routinely determining the MGMT status in all aggres-
sive pituitary tumors by immunochemistry [81]. Addition-
ally, response to TMZ in the first 3 months of treatment is 
considered a useful predictor of and drug discontinuation is 
advised if radiological progression is demonstrated after that 
interval [80, 81]. On the other hand, Ki-67 labelling index 
and p53 protein expression have not been confirmed to be 
of value in this setting [83, 92].
Other cytotoxic agents
Cytotoxic agents other than TMZ have been rarely used in 
the treatment of aggressive pituitary tumors and carcinomas 
and the experience with these drugs is limited to isolated 
case reports. Amongst them, lomustine and 5-fluorouracil 
are the most frequently offered due to their ability to pen-
etrate the central nervous system. In a series reporting four 
lactotroph-derived tumors (three carcinomas and one locally 
invasive adenoma), all of them previously surgically man-
aged and considered DA-resistant, this combination led to a 
partial response only in the least aggressive one [94]. Other 
studies described combinations of different chemothera-
peutic agents, such as procarbazine and vincristine without 
therapeutic success [95, 96].
Tyrosine kinase inhibitors
The epidermal growth factor receptor (EGFR) pathway has 
attracted interest as a potential therapeutic target for resist-
ant and aggressive pituitary tumors, mainly lactotroph and 
corticotroph ones [97]. Several receptor subtypes from this 
family have been identified in prolactinomas, and different 
expression profiles have been associated to tumor invasive-
ness, symptoms, and response to DAs [98, 99]. Notably, a 
higher expression of the ErbB3 receptor of this family in 
prolactinomas was associated with optic chiasm compres-
sion, suprasellar extension, carotid artery encasement, and 
with a better response to DA treatment [99].
Tyrosine kinase inhibitors (TKIs) block EGFR signal 
transduction cascades and in primary cultures of human 
prolactinomas, they reduce prolactin levels [100]. Two DA-
resistant patients with aggressive lactotroph tumors have 
received treatment with lapatinib for a 6-month period. The 
first case achieved near normalization of prolactin and a 22% 
reduction in tumor volume, while the second one demon-
strated a 42% reduction in prolactin levels and tumor stabi-
lization [99]. These encouraging results are currently fur-
ther explored in an ongoing phase II clinical trial in patients 
with DA-resistant prolactinomas [101]. Bevacizumab, a 
TKI targeting vascular endothelial growth factor (VEGF), 
has shown to partially suppress the proliferation of tumor 
stem-like cells isolated from rat prolactinoma [102]. This 
compound showed promising results in the treatment of cor-
ticotroph carcinomas but there is still no reported experience 
with prolactinomas [103, 104].
Inhibitors of mammalian target of rapamycin 
(mTOR)
The PI3K/Akt/mTOR pathway is an intracellular signaling 
system regulating the cell cycle and its overactivity has been 
associated with several cancers [105]. Anti-proliferative 
responses to the inhibition of the mammalian target of rapa-
mycin (mTOR) pathway have been reported in in vitro stud-
ies with aggressive pituitary tumors [106]. Particularly for 
prolactinomas, Gorvin et al. showed that certain variants of 
the prolactin receptor, like the Asn492Ile one, are associated 
with increased signaling by this pathway and cellular prolif-
eration, and that everolimus was antagonizing these effects 
[107]. A case report described a patient with a DA-resistant 
prolactinoma that underwent multiple surgical resections 
and radiotherapy 6 years before a trial of everolimus (10 mg/
day) was attempted [108]. After starting this agent, a 44% 
decrease in prolactin levels was observed and tumoral size 
was stable at the 1-year imaging re-evaluation. In this case, 
hyperglycemia, hypogeusia and mouth sores were reported 
as side effects. However, the same drug has been associated 
with disappointing outcomes in patients with aggressive cor-
ticotroph adenomas, underlining the need for larger studies 
[109, 110].
Other pharmacologic agents
In addition to the aforementioned drug classes, there are 
others described as potentially useful in the treatment DA-
resistant prolactinomas with evidence based only on pre-
clinical studies.
The TGF-β1 cytokine is intimately associated with 
fibrotic responses in different organs and tissues. Hu et al. 
reported that about 43% of the DA-resistant prolactinomas 
were highly fibrotic and had a higher collagen content than 
the DA-responsive ones [79]. In addition, the expression 
of TGF-β1/Smad3 signaling pathway-related proteins was 
elevated in DA-resistant and fibrotic prolactinomas and the 
compound SB431542, an inhibitor of this pathway, coun-
teracted these effects. A further publication reinforced these 
results, but others have reported opposite outcomes [29, 111, 
112]. No studies in prolactinoma patients have been yet con-
ducted with this drug.
A single study showed that chloroquine, an old drug 
used in malaria treatment, enhanced cabergoline-induced 
autophagy and apoptosis in prolactinoma cells in  vitro 
[113]. The same paper also investigated two animal models 
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in which chloroquine increased tumor suppression, allow-
ing cabergoline to exert its effects at a lower dose. The sig-
nificance of these findings in clinical practice remain to be 
elucidated.
Conclusions and future perspectives
Primary or secondary resistance to DAs represent challeng-
ing clinical scenarios. This is particularly true for aggressive 
prolactinomas in which surgery and radiotherapy may not 
achieve tumor control. In these settings, alternative medical 
treatments have been considered but data on their efficacy 
should be interpreted within the constraints of publication 
bias and of lack of relevant clinical trials. The limited reports 
on SSAs have shown conflicting results, but, nonetheless, 
cases with optimal outcomes have been documented. Data 
on estrogen modulators and metformin are scarce and their 
usefulness remains to be evaluated. In aggressive lacto-
troph PitNETs, temozolomide has demonstrated optimal 
outcomes, whereas for other cytotoxic agents, TKIs and for 
mTOR inhibitors, higher quality evidence is needed. Finally, 
promising preliminary results from in vitro and animal 
reports need to be validated and translated in human studies.
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